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Summary Eighteen patients with advanced breast cancer were commenced on treatment with high dose
doxorubicin (100mgm2) or doxorubicin (100 mgm-2) and cyclophosphamide (500 mg m-2) at 2 weekly
intervals. Three cycles of treatment were planned. rG-CSF was given subcutaneously for 10 days, starting 24 h
after each cycle of chemotherapy. Sixteen out of 18 patients responded (89%) of whom six (33%) achieved a
complete remission. Twelve (67%) completed the three planned cycles, four (22%) received two cycles and two
(11%) received one cycle only. The median time to progression was 51 months and the median survival was
18j months. Neutropenia occurred after 89% of courses and 65% of courses were accompanied by a
significant (WHO grade III or IV) infection. The duration of neutropenia was short (mean 5.4 days) and mean
time to absolute neutrophil count recovery (ANC > 1,000 x 106 litre) from the start of treatment was 11 days.
Moderate to severe epithelial toxicity (WHO grade 3 or 4) accompanied 43% of courses and was dose limiting.
Conclusion: High dose, dose intensive chemotherapy has an excellent initial therapeutic effect in advanced
breast cancer but does not prolong duration of remission or overall survival beyond that of standard
treatment. Although subcutaneous rG-CSF curtailed the expected duration of neutropenia substantially, the
overall incidence of neutropenia and of infections requiring intravenous antibiotics was high. Furthermore,
almost half of the courses were complicated by moderate to severe oral mucositis and/or mild to moderate
palmar and plantar inflammation. The lack of survival benefit and excess toxicity seriously limits the wider
application of this regime. It should not be used in place of standard dose palliative chemotherapy for
metastatic breast cancer.
Doxorubicin has been in clinical use for a period of over 15
years and has emerged as one of the most effective drugs in
the treatment of metastatic breast cancer. The objective res-
ponse rates to doxorubicin are largely dose related. Low dose
regimes (<60 mg m2 per 3 weeks) achieve a low response
rate (approximately 30%) and a particularly low rate of
complete remission (Gundersen et al., 1986; Carmo-Pereira et
al., 1987; Gundersen et al., 1990; Jonsson et al., 1991). The
response to conventional dose doxorubicin (60-70 mg m2
per 3 weeks) and to combination regimes containing doxo-
rubicin are of the order of 50-60% (Carmo-Pereira et al.,
1987; Steiner et al., 1983 and many others). At high doses
() 100 mg m-2 per 3 weeks) response rates of over 80% have
been reported in breast cancer patients (Jones et al., 1987,
1990; Bronchud et al., 1989). Cyclophosphamide shows a
similar, if less dramatic increase in effectiveness at increasing
doses (Bramwell et al., 1983; Frei et al., 1989).
The importance of drug scheduling and dose intensity on
efficacy and toxicity of treatment have been increasingly ap-
preciated. When the total dose of two regimes are equivalent,
the dose intensity may be of critical importance as
exemplified by the lower efficacy of 35 mg m-2 doxorubicin
(q 3 weeks x 16) when compared to 70 mgm2 doxorubicin
(q 3 weeks x 8) (Carmo-Pereira et al., 1987). In a randomised
study comparing the effect of scheduling on treatment out-
come, there was no difference bet*een the equi-dose intensive
regimes of doxorubicin 25 mgM2 (weekly x 12) versus
75 mg m-2 (3 weekly x 4 (Richards et al., 1992). The relative
importance of these two parameters is unknown when high
dose doxorubicin is used. In a previous study by Bronchud et
al. (1989) the response rate achieved with > 125 mg m-2 per
2 weeks (100%) appeared as good as, if not superior to a
higher dose, but less dose intensive regime of 135 mg m-2 per
4 weeks (85%) (Jones et al., 19P7). Both treatments were
accompanied by substantial epithelial and haematological
toxicity which on occasions, delayed subsequent treatments.
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The question then arises whether reducing the dose of dox-
orubicin further, whilst maintaining a dose intensive schedule
would result in lesser toxicity without loss of treatment
efficacy. To this end we have investigated the effects of
doxorubicin given at 100 mgm2 at 2 weekly intervals in 18
patients with metastatic breast cancer. The first nine patients
also received 500 mg m-2 cyclophosphamide and dose accel-
eration up to 2000 mg m-2 was intended. The epithelial tox-
icity of the combination chemotherapy appeared greater than
expected and in consequence the remaining nine patients
were treated with doxorubicin alone.
The major toxicity of this regime was expected to be
myelosuppression, particularly neutropenia. Myelosuppres-
sive effects of chemotherapy can be mitigated in part by use
of recombinant haemopoietic growth factors which stimulate
the proliferation and maturation of haemopoietic cells in the
bone marrow (Bronchud et al., 1988; Groopman et al., 1989;
Hermann et al., 1989). One of these factors, rG-CSF, stim-
ulates granulocyte proliferation in vivo (Souza et al., 1986;
Cullor et al., 1990) and when given by continuous intra-
venous infusion, can reduce the duration of neutropenia in
patients with chemotherapy induced myelosuppression (Bron-
chud et al., 1987; 1989). In order to circumvent the need for
central venous cannulation and an ambulatory pump system,
we have tested the efficacy of rG-CSF given subcutaneously
as an md or bd bolus in the above 18 patients receiving high
dose doxorubicin or doxorubicin and cyclophosphamide.
Methods
Eighteen women with inoperable locally advanced or metas-
tatic breast cancer were studied. Thirteen women were re-
cruited at the Christie Hospital and Holt Radium Institute
and five were from Guy's Hospital, London. All patients had
at least one site of measurable or evaluable disease and a
performance status of 0 to 2 on the WHO performance scale.
Patients had received no prior chemotherapy for advanced
disease. Those previously treated with surgery, endocrine
therapy (Tamoxifen, Megestrol Acetate) adjuvant chemo-
therapy or adjuvant radiotherapy were eligible and included.
Pre-treatment assessment included a medical history and
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full physical examination, chest X-ray, bone scan, cardiac
ejection fraction, ECG, bone marrow aspiration and trephine
and baseline laboratory investigations (FBC, plateles, coagu-
lation, serum urea and electrolytes, liver function tests, LDH,
G-CSF antibodies and urinalysis). Ultrasound scanning of
the liver was performed if the LFTS were abnormal or in the
presence of hepatomegaly. Patients with a history of cardiac
disease or evidence of cardiac dysfunction and patients with
an AST elevated more than twice normal values were ex-
cluded.
The treatment schedule is depicted in Figure 1. Dox-
orubicin was administered as a slow intravenous bolus at a
dose of 100 mg m2. In addition half of the patients (9/18
patients) received an intravenous bolus of cyclophosphamide
at a dose of 500 mg m-2. Chemotherapy was repeated at an
interval of 14 days for a maximum of three courses. All
patients had a full physical examination, baseline laboratory
tests, radiological reassessment, ECG and cardiac ejection
fraction prior to each cycle of treatment. A full blood count
and platelet count were performed routinely three times a
week and daily during the period of neutropenia. Chemo-
therapy was delayed if the total neutrophil count was less
than 2500 x 10 1'- or platelets less than 100 x 109 - 1, in the
presence of unresolved infection or mucositis, or if the
performance status deteriorated to WHO grade 3 or 4. Treat-
ment was reinstituted when the symptoms and signs of tox-
icity subsided.
Recombinant human granulocyte stimulating factor (rG-
CSF) was supplied by Chugai Pharmaceutical Company,
Japan. It was produced in chinese hamster ovary cells after
transformation with a vector derived from a human squa-
mous carcinoma cell line (CHU-2) which produces G-CSF
constitutively and is sequence identical to native human G-
CSF. rG-CSF was supplied as a sterile lyophilised powder
which was reconstituted with normal saline, and administered
by subcutaneous injection for 10 days, starting 24 h after
each cycle of chemotherapy. Following a preliminary dose
ranging study with rG-CSF an initial dose of 5 mcg kg-' was
selected. Successive dose escalation to 10 mcg kg- day- ' and
1Omcg kg-' bd was permitted if there was grade IV neu-
tropenia in the preceeding treatment cycle.
Response and toxicity were recorded in accordance with
the UICC criteria (Hayward et al., 1977). Briefly a complete
response was defined as the complete disappearance of all
signs of active disease for a minimum of 4 weeks. A partial
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Figure 1 Schema for administration of chemotherapy (AC/A)
and subcutaneous rG-CSF.
response required a reduction of more than 50% in the sum
of the products of the largest perpendicular axis of meas-
urable lesions or a 50% decrease in evaluable lesions for at
least 4 weeks. Progression was defined as a more than 25%
increase in the size of existing measurable lesions or the
appearance of any new lesions and stabilisation if there was
no change which amounted to a partial response or progres-
sion. In view of the very short duration of treatment, bone
disease was not considered evaluable for response at the end
of the treatment period (6 weeks) except when there was clear
evidence ofprogression, e.g: new lytic lesions. Pleural disease
was not evaluable. All patients gave written informed consent
and the study was conducted with the approval of the South
Manchester Ethics Committee and the Guy's Hospital Ethics
Committee.
Results
The pre-treatment characteristics of patients are shown in
Table I. All 18 patients were evaluable for response, toxicity
and survival. The median follow up time was 18 months
(range 2.5-26 months). Twelve patients (67 per cent) com-
pleted all three cycles of treatment, four patients (22%)
completed two cycles and two patients (11%) received one
cycle of treatment. Treatment was stopped in one patient
because of a significant decrease in cardiac ejection fraction.
Five others stopped because of a combination of factors
including infection, mucositis and reduced performance sta-
tus. On average, the second cycle of chemotherapy was
delayed by 2.2 days (range 0-8 days) and the third cycle by
3.6 days (range 0-11 days). Principal reasons for treatment
Table I Pre-treatment characteristics
No of patients
Age (median)
Prior therapy for primary disease
Previous treatment at relapse
No of sites of disease
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delay were infection associated with neutropenia and muco-
sitis (seven courses), oral mucositis with neutropenia (two
courses), neutropenia alone (two courses), oral mucositis
alone (one course) and general debility (one course). Two
courses were delayed for convenience.
course was 11 days (range 0-22 days). Figure 3 shows the
ANC profile of a typical patient and of two patients who had
exceptional haematological toxicity. One patient (GE) failed
to become neutropenic after each of three treatments. Ano-
ther patient (AH) with bone marrow involvement had a low
initital increment of ANC at 48 h (increased by 1.36 times)
and a long time to recovery (14 days) after the first course.
Response
Anti-tumour effects
Sixteen out of 18 patients responded (89%). Six patients
achieved a complete response (33%) including two patients
with liver metastases and one patient with bone marrow
infiltration. Ten patients achieved a partial response (56%)
including one patient who had a delayed response in the
breast after 10 weeks. Stabilisation for a period of 3 months
occurred in two patients (11%) with lung and liver metas-
tases in addition to other sites of disease. No patient pro-
gressed on this treatment. Interestingly of the 16 patients
who responded 11 responded rapidly after just one course of
chemotherapy (three CR, eight PR). There were two addi-
tional responses after the second course (five CR, eight PR)
and two further responses occurred after the third course of
chemotherapy. One patient was not evaluated until the third
course was completed.
The median time to progression was 166 days (5.5 months,
range 1.5-8.5 months) and all patients had progressed by
18.4 months. Eleven patients (61%) were alive at 1 year and
8 patients (44%) survived 2 or more years. The median
duration of survival was 18 months (range 2.5-26 months).
The median time to progression ofpatients who received 1 or
2 courses (74 days) was significantly shorter than those com-
pleting three courses (224 days P<0.02) but there was no
difference in survival between the two groups.
Toxicity
There were no treatment related deaths. Forty-eight hours
after starting rG-CSF (day 4) the absolute neutrophil counts
were increased by an average of 5.6 times (range 1.4-14.7) of
the baseline values and counts of up to 75,000 x 106 neutro-
phils per litre were recorded. The frequency of haematologi-
cal toxicity and infection are shown in Table II. Neutropenia
(WHO grade III or IV) accompanied 89% of courses. Figure
2 shows the median absolute neutrophil count (ANC) of all
patients during the first and third courses of treatment. The
majority of patients (95%) had an ANC of less than 1,000 x
106 litre 8 days after treatment. The initial onset of the nadir
was presumed to occur on day 5 or 6 as no patient was
neutropenic on day 4. The mean duration of neutropenia was
5.4 days (0-13 days) and the average number of days to
recovery (ANC > 1,000 x 106 litre) after the start of each
Table II Haematological toxicity and infections
Number of courses given = 46
WHO grade No of courses









































Figure 2 Median and interquartile range of ANC recorded in
patients during cycle one a, and cycle 3 b, of chemotherapy with
10 days subcutaneous rG-CSF. Number of patients measure-
ments at each time point are shown adjacent to range bars.
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Figure 3 Absolute neutrophil count of three individuals during
three courses of chemotherapy each with 10 days subcutaneous
G-CSF. AH: *--- Bone marrow involvement. Period of neutro-
penia decreased with successive treatments. PL: 0--- Neutropenia
after each treatment but no delays. GE: 0- No neutropenia, no
treatment delays.
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After the third course the increment of ANC at 48 h was
seven times baseline value and the time to recovery (11 days)
had improved considerably and were comparable to those of
patients without bone marrow infiltration.
Sixty-five per cent of courses (30/46) were accompanied by
WHO grade III or IV infection (Table II) requiring inpatient
treatment with broad spectrum antibiotics. Infection was
confirmed by positive blood cultures in three cases and the
following organisms were isolated: Pseudomonas aeroginosa,
haemolytic Streptococcus, Staphylococcus aureus and group
G Streptococcus. Prophylactic platelet transfusions were ad-
ministered when the platelet counts were less than 20 x 109
litre and were required after 18 courses. All but two patients
required blood transfusion for treatment related anaemia on
one or two occasions. There was no significant difference in
time to neutrophil recovery, neutrophil increments with rG-
CSF, and red cell and platelet transfusion requirements
between treatments courses 1, 2 and 3, indicating that
myelosuppression was not cumulative.
The time to onset of nadir, duration of neutropenia and
days to recovery, were not affected by altering the schedule
of rG-CSF from once daily to twice daily, nor by increasing
the dose from 5 mcgkg-' per day up to 20 mcg kg-' per day.
Table III shows non-haematological toxic effects. Nausea
and/or vomiting were experienced in 100% of courses but
were mild to moderate in severity in all but four courses.
Moderate to severe oral mucositis accompanied 43% of
courses and 10% had associated genital ulceration. Palmar
and plantar inflammation occurred after 43% of courses and
was moderate to severe in two patients. One patient required
surgical incision of a pseudo contracture of the palm formed
by exfoliated keratin scale. There was no difference in
severity or duration of mucocutaneous symptoms between
patients receiving the doxorubicin/cyclosphosphamide com-
bination and doxorubicin alone.
Minor transient abnormalities of liver function (WHO
grade I rise in AST or ALK phos) were observed in four
patients with previously normal values. All returned to nor-
mal in the post treatment period. The cardiac ejection frac-
tion was significantly reduced in two patients. One patient
was withdrawn from the trial after two courses (cumulative
dose of doxorubicin 200mgm2) and one had a reduced
cardic ejection fraction after the third treatment cycle (cumu-
lative dose of doxorubicin 300 mgm2). In both cases, the
cardiac ejection fraction was within the normal range and
there was no clinical evidence of cardiac failure. All patients
were alopecic. There were no toxic effects directly attri-
butable to the rG-CSF.
Discussion
We report an excellent initial therapeutic effect using an
intensive regime of doxorubicin alone or with conventional
dose cyclophosphamide in patients with locally advanced or
disseminated breast cancer. The overall response rate of 89%
(33% CR) compares favourably with that of previous studies
using high dose doxorubicin (Bronchud et al., 1989; Jones et
al., 1987) and with ablative therapy and autologous bone
marrow transplantation (Jones et al., 1990; Tagima et al.,
1989, 1988). Particular advantages were the short duration of
treatment (three treatments at approximately 2 weekly inter-
vals) and rapid onset of therapeutic effect with most res-
ponses occurring after one or two treatments. Although
rapidly achieved, responses were not durable. Some individ-
Table III Non-haematological toxicity
Number of courses = 46
WHO grade No of courses
Nausea/vomiting 1-2 42
3-4 4






uals relapsed as early as 1.5 months and the median time to
progression (5.5 months) was disappointingly similar to that
of standard treatment regimes. Likewise, overall survival was
not prolonged beyond that achievable by standard dose dox-
orubicin (Carmo-Pereira et al., 1987).
Predictably, neutropenia accompanied most cycles of treat-
ment. By utilising rG-CSF, the expected duration of neut-
ropenia was shortened, enabling treatment to be given at
approximately 21 week intervals and achieving a dose inten-
sity of up to two times standard. Nonetheless, moderate to
severe infections requiring intravenous antibiotics accom-
panied 65% of courses, indicating that even a short neut-
ropenic episode carries a high risk of serious infection. Thus,
the advantage of reduced duration of neutropenia lies in the
concomitant reduction in expected number of days spent in
hospital receiving intravenous antibiotics.
The major non-haematological toxicity was mucositis
affecting the oral cavity and perineum and palmar and plan-
tar exfoliation. Oral mucositis severe enough to preclude
eating solids was commonplace (43% of courses) and cont-
ributed significantly to overall discomfort between
treatments. In addition, frequent disruption of mucosal bar-
riers may have been a major factor contributing to infections
during periods of neutropenia. These mucocutaneous effects
were wholly attributed to doxorubicin as they were
experienced equally by patients receiving doxorubicin alone
and in combination with cyclophosphamide. Although it
rarely warranted treatment delay per se, the epithelial toxicity
was of sufficient severity to be dose limiting.
The importance of this study is three fold. It shows that
rG-CSF given by a daily subcutaneous bolus for 10 days can
substantially ameliorate the expected granulosuppressive tox-
icity of high dose doxorubicin. In this respect, it appears just
as effective as continuous intravenous rG-CSF given over 14
days, (Bronchud et al., 1989) and has the advantage of
greater convenience and avoiding some of the potential prob-
lems ofcentral venous access. Secondly, this study defines the
upper limit of bolus doxorubicin dose (100 mg m2/2 weeks) at
which mucositis is limiting. Thirdly, it confirms that high
dose doxorubicin is an effective, if toxic inducing agent.
Whilst the degree of toxicity incurred may be acceptable in
selected patients undergoing ablative therapy with/without
bone marrow transplantation, it precludes wider application
of high dose doxorubicin as first line therapy for metastatic
breast cancer. Existing standard treatment regimes for the
palliation of breast cancer remain unchallenged.
It is a pleasure to acknowledge the help of Lynn van de Water,
Valerie Goode (research nurses), Linda Ashcroft, David Ryder
(Statistics) and Maria Middleton (Secretarial).DOXORUBICIN AND CYCLOPHOSPHAMIDE IN BREAST CANCER TREATMENT 829
References
BRAMWELL, V.H.C., HOWELL, A., ANDERSON, H. & RANKIN, E.M.
(1983). Intermediate dose single agent cyclophosphamide chemo-
therapy of advanced cancer. Clin. Oncol., 9, 251-256.
BRONCHUD, M.H., POTTEN, M.R., MORGENSTERN, G., BLASCO,
M.J., SCARFFE, J.H., THATCHER, N., CROWTHER, D., SOUZA,
L.M., ALTON, N.K., TESTA, N.G. & DEXTER, T.M. (1988). In vitro
and in vivo analysis of the effects of recombinant human gran-
ulocyte colony-stimulating factor in patients. Br. J. Cancer, 58,
64-69.
BRONCHUD, M.H., HOWELL, A., CROWTHER, D., HOPWOOD, P.,
SOUZA, L. & DEXTER, T.M. (1989). The use of granulocyte
colony-stimulating factor to increase the intensity of treatment
with doxorubicin in patients with advanced breast and ovarian
cancer. Br. J. Cancer, 60, 121-125.
BRONCHUD, M.H., SCARFFE, J.H., THATCHER, N., CROWTHER, D.,
SOUZA, L.M., ALTON, N.K., TESTA, N.G. & DEXTER, T.M. (1987).
Phase I/II study of recombinant human granulocyte colony-
stimulating factor in patients receiving intensive chemotherapy
for small cell lung cancer. Br. J. Cancer, 56, 809-813.
CARMO-PEREIRA, J., COSTA, F.O., HENRIQUES, E., GODINHO, F.,
CANTINNO-LOPES, M.G., SALES-LUIS, A. & RUBENS, R.D.
(1987). A comparison of two doses of adriamycin in the primary
chemotherapy of disseminated breast carcinoma. Br. J. Cancer,
56, 471-473.
CULLOR, J.S., FAIRLEY, N., SMITH, W.L., WOOD, S.L., DELLINGER,
J.D., INOKUMA, M.S. & SOUZA, L.M. (1990). Hemogram changes
in lactating dairy cows given human recombinant colony stim-
ulating factor (r-methu g-csf). Vet. Pathol., 27, 311-316.
FREI, E., ANTMAN, K., TEICHER, B., EDER, P. & SCHNIPPER, L.
(1989). Bone marrow auto-transplantation for solid tumours-
prospects. J. Clin. Oncol., 7, 515-526.
GROOPMAN, J.E., MOLINA, J.M. & SCADDEN, D.T. (1989). Haemo-
poietic growth factors: biology and clinical applications. N. Eng.
J. Med., 321, 1449-1459.
GUNDERSEN, S., KVINNSLAND, S., KLEPP, O., KVALOY, S., LUND,
E. & HOST, H. (1986). Weekly adriamycin versus VAC in ad-
vanced breast cancer. A randomised trial. Eur. J. Cancer Clin.
Oncol., 22, 1431-1434.
GUNDERSEN, S., KVINNSLAND, S., KLEPP, O., LUND, E. & HOST, I.
(1990). Weekly adriamycin vs 4-epidoxorubicin every second
week in advanced breast cancer. A randomised trial. The Nor-
wegian Breast Cancer group. Eur. J. Cancer, 26, 45-48.
HAYWARD, J.L., RUBENS, R.D., CARBONE, P.P., HENSON, J.C.,
KUMAOKA, S. & SEGALOFF, A. (1977). Assessment of response
to therapy in advanced breast cancer. Br. J. Cancer, 35, 292-298.
HERRMANN, F., SCHULZ, G., LINDEMANN, A., MEYENBURG, W.,
OSTER, W., KRUMWIEH, D. & MERTELSMANN, R. (1989). Hae-
mopoietic responses in patients with advanced malignancy treated
with recombinant human granulocyte-macrophage colony stimu-
lating factors. J. Clin. Oncol., 7, 159-167.
JONES, R.B., HOLLAND, J.F., BHARDWAJ, S., NORTON, L., WIL-
FINGER, C. & STRASHUN, A. (1987). A phase I-II study of
intensive dose adriamycin for advanced breast cancer. J. Clin.
Oncol., 5, 172-177.
JONES, R.B., SHPALL, E.J., SHOGAN, J., AFFRONTI, M.L., CONIGLIO,
D., HART, L., HALPERIN, E., IGLEHART, J.D., MOORE, J., GOCK-
ERMAN, J., BAST, R.C. & PETERS, W.P. (1990). The Duke AFM
Programme. Intensive Induction chemotherapy for metastatic
breast cancer. Cancer, 66, 431-436.
JONSSON, P.E., MALMBERG, M., ERICSSON, M. & RYDELL, S.
(1991). Weekly dose adriamycin as first line chemotherapy in
advanced breast cancer. Anticancer Res., 11, 877-879.
MORIMOTO, A., SAKATA, Y., WATANABE, T. & MURAKAMI, N.
(1990). Leucocytosis induced in rabbits by intravenous or central
injection of granulocyte colony stimulating factor. J. Physiol.,
426, 117-126.
RICHARDS, M.A., HOPWOOD, P., RAMIREZ, A.J., TWELVES, C.J.,
FERGUSON, J.E., GREGORY, W.M., SWINDELL, R., SCRIVENER,
W., MILLER, J., HOWELL, A. & RUBENS, R.D. (1992). Dox-
orubicin in advanced breast cancer: Influence of schedule on
response, survival and quality of life. Eur. J. Cancer, 6/7, 1023-
1028.
SOUZA, L.M., BOONE, T.C., GABRILOVE, J., LAI, P.H., ZSEBO, K.M.,
MURDOCK, D.C., SCHAZIN, V.R., BRUSZEWSKI, J., LU, H.,
CHEN, K.K., BARENDT, J., PLATZER, E., MOORE, M.A.S., MER-
TELSMANN, R. & WELTE, K. (1986). Recombinant human granu-
locyte colony stimulating factor: effects on normal and leukaemic
myeloma cells. Science, 232, 61-65.
STEINER, R., STEWART, J.F., CANTWELL, B.J.M., MINTON, M.J.,
KNIGHT, R.K. & RUBENS, R.D. (1983). Adriamycin alone or
combined with vincristine in the treatment of advanced breast
cancer. Eur. J. Cancer Clin. Oncol., 19, 1553-1557.
TAJIMA, T., TOKUDA, Y., KUBOTA, M., ONTA, M., YOKOYAMA, S.,
MITOMI, T., NAKAMURA, Y., WATANABE, K., MURAKAMI, M.,
SHINOZUKA, T. (1988). Role of autologous bone marrow trans-
plantation in cancer chemotherapy. Gan-To Kasaku-Ryoko, 15,
3018-3024.
TAJIMA, H., TOKUDA, Y., ONTA, M., OKUMURO, A., NORIHISA, Y.,
KUBOTA, M., NOTO, T., FUJIMOTO, T., NAKASAKI, H., YOKO-
YAMA, S. (1989). Autologous bone marrow transplantation as a
measure against myelosuppression in cancer chemotherapy. Gan-
To-Kagaku-Ryoho., 4, 1085-1093.